Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat

Xenobiotica

Volumn 40, Issue 1, 2010, Pages 55-61

  Binkhathlan, Z ^a   Hamdy, D A ^a   Brocks, D R ^a   Lavasanifar, A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Metabolism; Pharmacokinetics; Protein binding; PSC 833; Valspodar

Indexed keywords

CREMOPHOR; VALSPODAR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RETENTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CYCLOSPORINS; GLYCEROL; INJECTIONS, INTRAVENOUS; LIVER; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 72949102194     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903331056     Document Type: Article

References (53)

1. Aicher L, Meier G, Norcross AJ, Jakubowski J, Varela MC, Cordier A, Steiner S. (1997). Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochem Pharmacol 53(5):723-731.
2. Aliabadi HM, Brocks DR, Lavasanifar A. (2005). Polymeric micelles for the solubilization and delivery of cyclosporine A: Pharmacokinetics and biodistribution. Biomaterials 26(35):7251-7259.
3. Aliabadi HM, Brocks DR, Mahdipoor P, Lavasanifar A. (2007). A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers. J Control Rel 122(1):63-70.
4. Aliabadi HM, Spencer TJ, Mahdipoor P, Lavasanifar A, Brocks DR. (2006). Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. Aaps J 8(4):E672-81.
5. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D. (1995). Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7(12):603-610.
6. Aszalos A, Thompson K, Yin JJ, Ross DD. (1999). Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticanc Res 19(2A):1053-1064.
7. Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C et al. (2001). A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92(6):1577-1590. (Pubitemid 32947844)
8. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM et al. (2004). A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10(14):4724-4733.
9. Binkhathlan Z, Somayaji V, Brocks DR, Lavasanifar A. (2008). Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 869(1-2):31-37.
10. Boesch D, Gaverieaux C, Jachez B, Loor F. (1991a). In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233.
11. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. (1991b). Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196(1):26-32.
12. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. (1996). Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14(2):610-618.
13. Brocks DR. (2000). Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. Biopharm Drug Dispos 21(9):365-371.
14. Brocks DR, Ala S, Aliabadi HM. (2006). The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27(1):7-16.
15. Brocks DR, Wasan KM. (2002). The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 91(8):1817-1826.
16. Cagliero E, Ferracini R, Morello E, Scotlandi K, Manara MC, Buracco P, Comandone A, Baroetto Parisi R, Baldini N. (2004). Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 12(5):1023-1031.
17. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M et al. (2001). Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19(3):832-842. (Pubitemid 32119099)
18. Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6(6):539-546.
19. Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstnar S, Sikic BI. (1998). Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother Pharmacol 41(6):517-521.
20. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095.
21. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M et al. (2001). Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 19(6):1589-1599.
22. Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schachinger H, Haefeli WE. (2000). Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 50(3):237-246.
23. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE. (1998). The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26(8):802-811.
24. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ. (2000). Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18(5):1124-1134.
25. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3(11):2005-2015.
26. Gottesman MM, Pastan I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
27. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52(5):453-457.
28. Hoppu K. (1999). Prehepatic metabolism of drugs - a mechanism for low and variable oral bioavailability. Pediatr Nephrol 13(1):85-89.
29. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC. (1992). Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51(3):433-438.
30. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. (2003). Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9(7):2849-2855.
31. Kivisto KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 40(6):523-530.
32. Kovarik JM, Mueller EA, Richard F, Tetzloff W. (1997). Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate. J Clin Pharmacol 37(11):1009-1014.
33. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K. (1998). Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 89(11):1220-1228.
34. Lemaire M, Bruelisauer A, Guntz P, Sato H. (1996). Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistancereversing cyclosporin, in rats. Cancer Chemother Pharmacol 38(5):481-486.
35. Loor F. (1999). Valspodar: Current status and perspectives. Expert Opin Investig Drugs 8(6):807-835.
36. Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD. (1997). Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 37(2):123-128.
37. Ma MK, McLeod HL, Westervelt P, Fracasso PM. (2002). Pharmacokinetic study of infusional valspodar. J Clin Pharmacol 42(4):412-418.
38. Mueller EA, Kovarik JM, Uresin Y, Preisig-Fluckiger SS, Hensel S, Lucker PW, Holt B. (1997). Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. J Clin Pharmacol 37(11):1001-1008.
39. Naito M, Watanabe T, Tsuge H, Koyama T, Oh-Hara T, Tsuruo T. (1996). Potentiation of the reversal activity of SDZ PSC833 on multidrug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int J Cancer 67(3):435-440.
40. Ortega I, Rodriguez M, Suarez E, Perez-Ruixo JJ, Calvo R. (2007). Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar. Pharm Res 24(7):1299-1308.
41. Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. (1992). SDZ PSC 833 and SDZ 280-446 are the most active of various resistance- modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drug 3(4):419-425.
42. Schuhmacher J, Buhner K, Witt-Laido A. (2000). Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 89(8):1008-1021.
43. Simon N, Dailly E, Combes O, Malaurie E, Lemaire M, Tillement JP, Urien S. (1998). Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 45(2):173-175.
44. Smith AJ, Mayer U, Schinkel AH, Borst P. (1998). Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90(15):1161-1166.
45. Song S, Suzuki H, Kawai R, Sugiyama Y. (1999). Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27(6):689-694.
46. Song S, Suzuki H, Kawai R, Tanaka C, Akasaka I, Sugiyama Y. (1998). Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26(11):1128-1133.
47. Tai HL. (2000). Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther 2(4):459-467.
48. Vickers AE, Fischer V, Connors S, Fisher RL, Baldeck JP, Maurer G, Brendel K. (1992). Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos 20(6):802-809.
49. Wagner O, Schreier E, Heitz F, Maurer G. (1987). Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 15(3):377-383.
50. Watanabe T, Nakayama Y, Naito M, Oh-Hara T, Itoh Y, Tsuruo T. (1996). Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs 7(8):825-832.
51. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. (1995). Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34(2):235-241.
52. Watkins PB. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 10(4):235-250.
53. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. (1995). Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58(5):492-497